NASDAQ:ADMS - Adamas Pharmaceuticals Stock Price, Forecast & News

Adamas Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMS."

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) posted its quarterly earnings data on Thursday, November, 7th. The specialty pharmaceutical company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by $0.09. The specialty pharmaceutical company had revenue of $13.93 million for the quarter, compared to analyst estimates of $14.36 million. Adamas Pharmaceuticals had a negative return on equity of 205.30% and a negative net margin of 215.09%. View Adamas Pharmaceuticals' Earnings History.

Adamas Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 2nd 2020. View Earnings Estimates for Adamas Pharmaceuticals.

Adamas Pharmaceuticals issued an update on its FY 2019 Pre-Market earnings guidance on Wednesday, January, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $54.6-54.6 million, compared to the consensus revenue estimate of $53.65 million.

10 analysts have issued twelve-month price targets for Adamas Pharmaceuticals' stock. Their forecasts range from $5.00 to $55.00. On average, they anticipate Adamas Pharmaceuticals' stock price to reach $15.67 in the next twelve months. This suggests a possible upside of 197.3% from the stock's current price. View Analyst Price Targets for Adamas Pharmaceuticals.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adamas Pharmaceuticals in the last year. There are currently 2 sell ratings, 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Adamas Pharmaceuticals.

Media headlines about ADMS stock have been trending somewhat positive recently, InfoTrie Sentiment reports. The research firm scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Adamas Pharmaceuticals earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave news articles about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Adamas Pharmaceuticals.

Adamas Pharmaceuticals saw a increase in short interest in the month of January. As of January 15th, there was short interest totalling 2,380,000 shares, an increase of 28.6% from the December 31st total of 1,850,000 shares. Based on an average daily trading volume, of 641,000 shares, the days-to-cover ratio is currently 3.7 days. Approximately 10.7% of the company's shares are short sold. View Adamas Pharmaceuticals' Current Options Chain.

Some companies that are related to Adamas Pharmaceuticals include AC Immune (ACIU), Kadmon (KDMN), Morphic (MORF), Crinetics Pharmaceuticals (CRNX), Magenta Therapeutics (MGTA), Kura Oncology (KURA), Prothena (PRTA), MacroGenics (MGNX), Milestone Pharmaceuticals (MIST), Atreca (BCEL), Neoleukin Therapeutics (NLTX), BioDelivery Sciences International (BDSI), CytoDyn (CYDY), Molecular Templates (MTEM) and Clovis Oncology (CLVS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Adamas Pharmaceuticals investors own include Rite Aid (RAD), Sangamo Therapeutics (SGMO), Agile Therapeutics (AGRX), Abeona Therapeutics (ABEO), Amarin (AMRN), Exelixis (EXEL), ACADIA Pharmaceuticals (ACAD), Ardelyx (ARDX), Cara Therapeutics (CARA) and Century Aluminum (CENX).

Adamas Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Deltec Asset Management LLC (1.43%) and California Public Employees Retirement System (0.06%). Company insiders that own Adamas Pharmaceuticals stock include Alfred G Merriweather, Christopher B Prentiss, Gregory T Went, Jennifer J Rhodes, Rajiv Patni and Richard King. View Institutional Ownership Trends for Adamas Pharmaceuticals.

ADMS stock was sold by a variety of institutional investors in the last quarter, including Deltec Asset Management LLC. Company insiders that have sold Adamas Pharmaceuticals company stock in the last year include Alfred G Merriweather, Christopher B Prentiss, Gregory T Went and Jennifer J Rhodes. View Insider Buying and Selling for Adamas Pharmaceuticals.

ADMS stock was acquired by a variety of institutional investors in the last quarter, including California Public Employees Retirement System. View Insider Buying and Selling for Adamas Pharmaceuticals.

Shares of ADMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ADMS stock can currently be purchased for approximately $5.27.

Adamas Pharmaceuticals has a market capitalization of $146.82 million and generates $34.05 million in revenue each year. The specialty pharmaceutical company earns $-131,000,000.00 in net income (profit) each year or ($4.87) on an earnings per share basis. Adamas Pharmaceuticals employs 159 workers across the globe.View Additional Information About Adamas Pharmaceuticals.

The official website for Adamas Pharmaceuticals is http://www.adamaspharma.com/.

Adamas Pharmaceuticals' mailing address is 1900 POWELL ST. SUITE 1000, EMERYVILLE CA, 94608. The specialty pharmaceutical company can be reached via phone at 510-450-3500 or via email at [email protected]